60 results
Page 2 of 3
424B5
gxllb agg5nqungzvu73
26 Apr 22
Prospectus supplement for primary offering
4:02pm
424B5
pphrg 4ejs57ojn5tp
25 Apr 22
Prospectus supplement for primary offering
4:03pm
DEFA14A
4kulp1l9jqzhwpq7l
21 Apr 22
Additional proxy soliciting materials
4:05pm
8-K
EX-99.1
8awunpakui2fa5t1pp
17 Mar 22
Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:11pm
8-K
EX-99.1
644c8hqw16m
10 Nov 21
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
4:14pm
424B5
d17goslhehmqc hmgbv
3 Sep 21
Prospectus supplement for primary offering
12:00am
S-3
g1qx4aohoy1v i1hv
12 Aug 21
Shelf registration
5:04pm
S-3
EX-1.2
8s398 rd426bhl6rmh7t
12 Aug 21
Shelf registration
5:04pm
8-K
EX-99.1
c9go5 znnek
12 Aug 21
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
4:19pm
8-K
EX-99.1
ctyzdpq755r u9sgk7ec
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-10.1
8bqaquy1
14 Jul 21
Entry into a Material Definitive Agreement
7:07am
8-K
EX-99.1
iakm u9mxkcfwm6df
13 May 21
Nkarta Reports First Quarter 2021 Financial Results and Business Progress
4:18pm
8-K
EX-99.1
1sbmy5r b9o
28 Apr 21
Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies
8:07am
DEFA14A
ng4ffbj6xso05aig8
22 Apr 21
Additional proxy soliciting materials
12:37pm